| Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 |
|---|---|---|---|---|---|
Gross Sales | 371.83 | 276.06 | 338.58 | 262.87 | 272.54 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 371.83 | 276.06 | 338.58 | 262.87 | 272.54 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 18.7 | 12.17 | 6.27 | 5.31 | 7.09 |
Total Income | 390.53 | 288.23 | 344.85 | 268.18 | 279.63 |
Total Expenditure | 324.47 | 259.88 | 307.17 | 234.68 | 240 |
PBIDT | 66.06 | 28.35 | 37.68 | 33.5 | 39.63 |
Interest | 0.03 | 0.04 | -0.03 | 0.12 | -0.14 |
PBDT | 66.03 | 28.31 | 37.71 | 33.38 | 39.77 |
Depreciation | 10.12 | 12.39 | 12.46 | 13.99 | 15.51 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 15.6 | 6.26 | 5.15 | 7.07 | 0 |
Deferred Tax | -0.27 | 4.92 | 2.74 | 1.2 | 9.92 |
Reported Profit After Tax | 40.58 | 4.74 | 17.36 | 11.12 | 14.34 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 40.58 | 4.74 | 17.36 | 11.12 | 14.34 |
Extra-ordinary Items | 9.91 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 30.67 | 4.74 | 17.36 | 11.12 | 14.34 |
EPS (Unit Curr.) | 30.35 | 3.54 | 12.98 | 8.32 | 10.73 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 13.37 | 13.37 | 13.37 | 13.37 | 13.37 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 17.76 | 10.26 | 11.12 | 12.74 | 14.54 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 10.91 | 1.71 | 5.12 | 4.23 | 5.26 |
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
